Erbb3 based methods and compositions for treating neoplasms
CA 2480099 C · Owner: Zensun (Shanghai) Sci-Tech. Ltd. · Inventors: Zhou, Mingdong
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to compositions and methods for treating neoplasms in mammals, particularly humans. More particularly the present , invention provides for methods for preventing treating or delaying neoplasm , in a mammal using an ErbB-3 protein a nucleic acid encoding an ErbB-3 protein or a functional fragment thereof. The present invention also provides for isolated nucleic acids encoding an extracellular domain of the ErbB-3 protein or a functional fragment thereof, substantially purified extracellular domain of the ErbB-3 protein, or a functional fragment thereof and antibodies that bind to an epitope in an extracellular domain of the ErbB-3 protein or a , functional …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 26, 2003 and granted January 8, 2019. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended March 26, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 26, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.